Efficacy and safety of ciclesonide, 200 μg once daily, for the treatment of perennial allergic rhinitis

In this study, intranasal ciclesonide treatment was associated with significant reductions in nasal symptoms and appreciable improvements in health-related quality of life in adult and adolescent patients with PAR. Ciclesonide was well tolerated, with a safety profile comparable with that of placebo.